Advisory Board Member at Portola Pharmaceuticals
David Ginsburg, M.D., is a James V. Neel Distinguished University Professor of Internal Medicine and Human Genetics, Warner-Lambert/Parke-Davis Professor of Medicine and a member of the Life Sciences Institute at the University of Michigan Medical School. He also is a Howard Hughes Medical Institute Investigator. For the past 25 years, Dr. Ginsburg has dedicated his career to understanding the components of the blood-clotting system and how disturbances in their function lead to human bleeding and blood-clotting disorders. His lab has studied the molecular basis of the common disorder von Willebrand disease and is identifying modifier genes that control severity for this and related diseases. His lab has also defined mutations in ADAMTS13, an enzyme that processes von Willebrand factor, as the cause of thrombotic thrombocytopenia purpura. Studies of the bleeding disease combined deficiency of factors V and VIII by his lab identified mutations in a novel pathway for the transport of a select subset of proteins from the endoplasmic reticulum to the Golgi. Dr. Ginsburg is a member of the Institute of Medicine of the National Academy of Sciences and the American Academy of Arts and Sciences.
Advisory Board Member